Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Other financing activities (2022 - 2024)

Tandem Diabetes Care's Other financing activities history spans 4 years, with the latest figure at $183000.0 for Q1 2024.

  • For Q1 2024, Other financing activities changed N/A year-over-year to $183000.0; the TTM value through Dec 2024 reached $183000.0, up 357.75%, while the annual FY2024 figure was $183000.0, 357.75% up from the prior year.
  • Other financing activities reached $183000.0 in Q1 2024 per TNDM's latest filing, up from -$71000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $183000.0 in Q1 2024 to a low of -$405000.0 in Q3 2022.
  • Average Other financing activities over 3 years is -$52500.0, with a median of $6000.0 recorded in 2022.
  • The largest YoY upside for Other financing activities was 82.47% in 2023 against a maximum downside of 82.47% in 2023.
  • A 3-year view of Other financing activities shows it stood at $83000.0 in 2022, then crashed by 185.54% to -$71000.0 in 2023, then skyrocketed by 357.75% to $183000.0 in 2024.
  • Per Business Quant, the three most recent readings for TNDM's Other financing activities are $183000.0 (Q1 2024), -$71000.0 (Q3 2023), and $83000.0 (Q4 2022).